Baird: Gilead Set For Q1 EPS Miss, But Hep C Trends Still Good Long Term
April 12, 2016 at 10:06 AM EDT
The first quarter earnings of Gilead Sciences, Inc. (NASDAQ: GILD) may miss the Street view, but promising Hep C Rx trends drive a ...
